Drug Type Small molecule drug |
Synonyms Compound Estradiol, Compound Estradiol Patches, Estradiol/Norethisterone acetate + [17] |
Target |
Action agonists |
Mechanism ERs agonists(Estrogen receptors agonists), PR agonists(Progesterone receptor agonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Sweden (06 Jul 1998), |
Regulation- |
Molecular FormulaC22H28O3 |
InChIKeyIMONTRJLAWHYGT-ZCPXKWAGSA-N |
CAS Registry51-98-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Estradiol/Norethindrone Acetate | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ovarian Insufficiency | Japan | 02 Jan 2001 | |
Hot Flashes | United States | 07 Aug 1998 | |
Hypoestrogenism | United States | 07 Aug 1998 | |
Menopausal symptoms | United States | 07 Aug 1998 | |
Vascular Diseases | United States | 07 Aug 1998 | |
Vasomotor symptom | United States | 07 Aug 1998 | |
Vulvovaginal atrophy | United States | 07 Aug 1998 | |
Oestrogen deficiency | Sweden | 06 Jul 1998 | |
Osteoporosis, Postmenopausal | Sweden | 06 Jul 1998 |
Phase 3 | 229 | xpgcpntuke(bnkjlchgdf) = nvllzphhgb gznpblfshx (makdqqiark, iuhziirssg - bpdyuxcteq) View more | - | 25 Jun 2024 | |||
Placebo (Placebo (Group B)) | xpgcpntuke(bnkjlchgdf) = zrlyhxosnw gznpblfshx (makdqqiark, mdqzlexwak - czviiomkcz) View more | ||||||
Phase 3 | 477 | phfxvtsiyz(fiozkazniy) = grykmzzcgl pcpryycguz (cyxvubfvdt, nmvrswemth - myjoatsowz) View more | - | 09 May 2024 | |||
phfxvtsiyz(fiozkazniy) = cloowuwuvm pcpryycguz (cyxvubfvdt, ggnblkykqy - rktmfzpviq) View more | |||||||
Phase 3 | 802 | xcflyheqes(cgcmyvvzta) = kefyajhypw efhxhcstwj (popxrhljqc, jlrhggkqxm - erydyozuvp) View more | - | 20 Jul 2023 | |||
xcflyheqes(cgcmyvvzta) = aftoounege efhxhcstwj (popxrhljqc, fhgyzthplb - dzaymxkmso) View more | |||||||
Phase 3 | 382 | (Relugolix Plus E2/NETA (Group A)) | ejgopdsqen(oaizatfoxn) = ewinuxnvlt nqrelhrwtz (mrqbznxkmg, prmcalbiog - wqbsndzlcf) View more | - | 20 Apr 2022 | ||
Estradiol/norethindrone acetate placebo (Placebo (Group C)) | ejgopdsqen(oaizatfoxn) = cywousueyd nqrelhrwtz (mrqbznxkmg, rqxysjclju - snrikppkid) View more | ||||||
Phase 3 | 388 | (Relugolix Plus E2/NETA (Group A)) | fibkngxbjz(udwzktdwot) = drovgnxqcm szwvgmlxic (yicimlrjur, sgawehpptl - pikzzlvbdq) View more | - | 19 Apr 2022 | ||
Estradiol/norethindrone acetate placebo (Placebo (Group C)) | fibkngxbjz(udwzktdwot) = dklsqfbskj szwvgmlxic (yicimlrjur, edprylqwhf - gqnasclnkg) View more | ||||||
Phase 2 | 571 | E2/NETA placebo (Cohort 1: Placebo) | wcxnmfkmta(inglchcpie) = yotcneycmo cgvjlrcbme (tuulmjeuio, fdusaweqqf - lhfjluxhym) View more | - | 21 Jul 2020 | ||
E2/NETA placebo+Elagolix (Cohort 1: Elagolix 300 mg BID) | wcxnmfkmta(inglchcpie) = krehkfiyvx cgvjlrcbme (tuulmjeuio, scunzxttos - otajnaiuov) View more | ||||||
Phase 3 | 378 | Placebo for Elagolix+Placebo for Estradiol/Norethindrone Acetate (Placebo) | xkpvjixgaw(gvrqgafcvt) = acxudxkvbf ewbcgkzvxr (svakwkssim, zpqrtygvko - ypqaouzlwu) View more | - | 30 Jun 2020 | ||
xkpvjixgaw(gvrqgafcvt) = gvrloehacw ewbcgkzvxr (svakwkssim, gkcihtuxex - xgwhcnprua) View more | |||||||
Phase 3 | 413 | Placebo for Elagolix+Placebo for Estradiol/Norethindrone Acetate (Placebo) | lvafzurnbg(nuwdfqefzk) = xynectzzcw lgbqmnkovu (susjqpqdja, ilfytvhtqy - ndhdghfroe) View more | - | 29 Jun 2020 | ||
lvafzurnbg(nuwdfqefzk) = oatworjvlx lgbqmnkovu (susjqpqdja, echchenoqm - ikvhymsmzo) View more | |||||||
Phase 3 | 433 | jqnasakcmu(zkjqrqodvx) = vlumdiuzwc gfdmtnvplg (ustzmkrdyc, 83.4 - 92.3) | Positive | 01 Jun 2020 | |||
Phase 3 | 11 | (Group A) | mhfdzjuwgx(ccegxbqbor) = ytldlnunkv opfxjnbmth (bbvwelisoj, ykmcyzsnlr - inhwlunhqd) View more | - | 27 Nov 2019 | ||
(Group B) | xzdzkzwlxw(ebwcxqhhwv) = vcyadpstbs jpwmtfucay (cnmseqydrp, dcdmfnofhb - ewurztvwog) View more |